Latest ThromboGenics NV Stories
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA(R) (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA(R) as an...
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it has commenced research and development of innovative protein therapeutics to address a novel ThromboGenics-identified biologic target implicated in a range of diabetic eye diseases such as diabetic macular edema (DME). ThromboGenics will utilize Eleven...
LEUVEN, Belgium, May 27, 2013 /PRNewswire/ -- Roll out in Finland and Norway to follow shortly ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) in Denmark and Sweden, the third and fourth European markets where the product is now available. Alcon will roll out the drug in Finland and...
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ -- - JETREA(R) gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million - Phase IIa study evaluating JETREA(R) in wet AMD patients shows 24% VMA resolution rate for JETREA(R)treated patients, versus 12% for sham injection. This positive trend and safety profile warrant further larger studies to confirm clinical...
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R)in Germany, the second European market where the product is now available. Since May 1st, 2013, JETREA(R)is listed in the "Lauer-Taxe" (Grosse Deutsche Spezialitatentaxe) with an ex-factory price of EUR3,078....
LEUVEN, Belgium, April 11, 2013 /PRNewswire/ -- First EU JETREA(R) order triggers EUR45 million milestone payment from Alcon to ThromboGenics ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today announces that its partner Alcon has launched JETREA(R) (ocriplasmin) in the UK, its first market in Europe....
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that the Company will start trading as part of the BEL20 index on the Euronext stock exchange today. The BEL20 index is a real-time index reflecting the continuous price evolution of the 20 most liquid Belgian shares listed on Euronext Brussels and serves as...
LEUVEN, Belgium, March 15, 2013 /PRNewswire/ -- EU approval of JETREA(R)triggers a EUR45 million milestone payment from Alcon ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that the European Commission has approved JETREA(R) (ocriplasmin) in the European Union. JETREA(R) is approved for the...
LEUVEN, Belgium, March 14, 2013 /PRNewswire/ -- Transformational 2012 Delivers Euro 30 Million in Net Profit REGULATED INFORMATION ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today issued a business update and its financial results for the full year ending December 31, 2012. The past 12 months have been a defining period for ThromboGenics,...
LEUVEN, Belgium, February 28, 2013 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), and co-development partner BioInvent International AB (OMXS: BINV), announce today the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children. The Cell publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role...
